Mealey's (February 5, 2020, 9:10 AM EST) -- SAN FRANCISCO — A shareholder sued a biopharmaceutical company and its CEO in California federal court on Jan. 23, alleging that the defendants concealed negative clinical trial results for the company’s bone marrow cancer treatment drug in violation of federal securities laws (Michael Tollen v. Geron Corp., et al., No. 20-547, N.D. Calif.)....